This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by AeRang Kim, Children's Research Institute
Sponsor:
Information provided by (Responsible Party):
AeRang Kim, Children's Research Institute
ClinicalTrials.gov Identifier:
NCT02076906
First received: January 28, 2014
Last updated: June 8, 2017
Last verified: June 2017
January 28, 2014
June 8, 2017
April 2014
January 2019   (Final data collection date for primary outcome measure)
Toxicity [ Time Frame: 28 days following ablative therapy ]
Toxicity will be evaluated using CTCAEv4. Adverse events will be summarized descriptively with tabulations of adverse event type, severity, and relationship to study treatment.
Same as current
Complete list of historical versions of study NCT02076906 on ClinicalTrials.gov Archive Site
  • Disease response [ Time Frame: Up to 1 year ]
    We will preliminarily define tumor response from MR-HIFU ablative therapy assessed according to a modified Response Evaluation Criteria in Solid Tumors (RECIST). We will also evaluate functional tumor response using FDG-PET post MR-HIFU ablative treatment for patients with PET avid target lesions.
  • Patient reported outcomes and quality of life measurements [ Time Frame: Up to 1 year ]
    We will use a validated symptom distress scale and quality of life metrics pre- and post-therapy at scheduled intervals.
  • Immune Markers [ Time Frame: Pre-treatment, 1 day post treatment, 7 days post treatment ]
    Changes in immune markers from baseline and post therapy will be evaluated.
Same as current
Not Provided
Not Provided
 
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
Safety and Feasibility Study of Using MR-guided High Intensity Focused Ultrasound (HIFU) for the Ablation of Relapsed or Refractory Pediatric Solid Tumors
The purpose of this study is to determine if Magnetic Resonance guided High Intensity Focused Ultrasound ablative therapy is safe and feasible for children with refractory or relapsed solid tumors.
Magnetic Resonance (MR)-guided high intensity focused ultrasound (HIFU) is an innovative technique that allows for non-invasive thermal ablation of tissue. Advantages over conventional local tumor control such as surgery, radiation, or radiofrequency are that MR-HIFU is completely non-invasive, non-ionizing, and enables ablation of large tumor volumes with avoidance of adjacent tissue injury. This study will evaluate the safety and feasibility of MR-HIFU ablative therapy in children with refractory or relapsed solid tumors that are located in bone or soft tissue in close proximity to bone. Children ≤ 21 years of age with refractory or relapsed solid tumors with measurable target lesions that are located in bone or soft tissue in close proximity to bone are eligible. Tolerability will be defined during the 28 days following MR-HIFU ablation. Patients will continue to be followed for tumor response and secondary outcomes for up to one year post ablation treatment.
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
  • Relapsed Pediatric Solid Tumors
  • Refractory Pediatric Solid Tumors
  • Tumors Located in Bone or Soft Tissue in Close Proximity to Bone
  • Rhabdomyosarcoma
  • Ewing Sarcoma
  • Osteosarcoma
  • Neuroblastoma
  • Wilms Tumor
  • Hepatic Tumor
  • Germ Cell Tumor
  • Desmoid Tumor
Device: Magnetic Resonance High Intensity Focused Ultrasound
MR-High intensity focused ultrasound (HIFU) is an ultrasound based technology which allows for non-invasive thermal ablation of tumors under the guidance of MR thermography.
Other Names:
  • MR-HIFU
  • HIFU
  • Philips Sonalleve
Experimental: MR-HIFU
Magnetic Resonance High Intensity Focused Ultrasound (MR-HIFU) ablative therapy for children with recurrent or relapsed solid tumors.
Intervention: Device: Magnetic Resonance High Intensity Focused Ultrasound
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
14
January 2019
January 2019   (Final data collection date for primary outcome measure)

AGE: ≤ 30 years of age.

DIAGNOSIS:

Histologically confirmed malignant solid tumors, which may include but are not limited to rhabdomyosarcoma and other soft tissue sarcomas, Ewing's sarcoma family of tumors, osteosarcoma, neuroblastoma, Wilms' tumor, hepatic tumors, germ cell tumors.

TUMOR LOCATION: Target lesion(s) must be located in bone or soft tissue in close proximity to bone. Target lesions must be reachable within the normal safety margins of HIFU as specified in the instructions for use.

TARGET LESION(S): Radiographically evaluable or measurable solid tumor target lesion(s).

THERAPEUTIC OPTIONS:

Malignant Tumor: The patient's cancer must have relapsed after or failed to respond to frontline curative therapy and there must not be other potentially curative treatment options available. Curative therapy may include surgery, radiation therapy, chemotherapy, or any combination of these modalities.

PRIOR THERAPY:

Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering on this study.

No limitation on the number of prior chemotherapy regimens that the patient may have received prior to study entry.

Myelosuppressive chemotherapy: The last dose of all myelosuppressive anticancer drugs must be at least 3 weeks prior to study entry.

Immunotherapy: The last dose of immunotherapy (monoclonal antibody or vaccine) must be at least 4 weeks prior to study entry.

Biologic (anti-cancer agent): The last dose of all biologic agents for the treatment of the patient's cancer (such as retinoids or tyrosine kinase inhibitors) must be at least 7 days prior to study entry.

Radiation therapy: The last dose of radiation to more than 25 % of marrow containing bones (pelvis, spine, skull) must be at least 4 weeks prior to study entry. The last dose of all other local palliative (limited port) radiation must be at least 2 weeks prior to study entry.

Stem Cell Transplantation. At least 2 months post-autologous stem cell transplant or at least 3 months post-allogeneic transplant and recovered from toxicities without evidence of graft versus host disease and on stable doses of immunosuppressive medications if required.

Growth Factors. The last dose of colony stimulating factors, such as filgrastim, sargramostim, and erythropoietin, must be at least 1 week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be at least 2 weeks prior to study entry.

CONCURRENT THERAPIES:

No other anti-cancer therapy (chemotherapy, biological therapy, radiation therapy) is permitted during HIFU treatment and post treatment follow up for tolerability (see section 3.3).

PERFORMANCE STATUS:

Patients > 10 years old must have a Karnofsky performance level ≥ 50%, and children ≤ 10 years old must have a Lansky performance level ≥ 50% (See Appendix I).

Patients who are unable to walk because of paralysis or motor weakness, but who are up in a wheelchair will be considered ambulatory for the purpose of calculating the performance score.

  • HEMATOLOGIC FUNCTION:

    1. Peripheral absolute neutrophil count (ANC) of ≥750/µL
    2. Platelet count ≥75,000/µL (may receive transfusions)
  • RENAL FUNCTION: Age-adjusted normal serum creatinine OR a creatinine clearance ≥60 mL/min/1.73 m2.
  • ADEQUATE PULMONARY FUNCTION: Defined as no dyspnea at rest, and a pulse oximetry >94% on room air if there is clinical indication for determination.
  • Normal PT, PTT and INR < 1.5 x ULN (including patients on prophylactic anticoagulation)

Exclusion Criteria:

Clinically significant unrelated systemic illness, such as serious infections, hepatic, renal or other organ dysfunction, which in the judgment of the Principal or Associate Investigator would compromise the patient's ability to tolerate the general anesthetic required for the procedure.

Target lesions that are pulmonary primary tumors or metastases.

Implant or prosthesis or scar tissue within the path of the HIFU beam.

Target <1 cm from nerve plexus, spinal canal, bladder, bowel

Target in contact with hollow viscera

Lesion in the skull

Inability to undergo MRI and/or contraindication for MRI

Inability to tolerate stationary position during HIFU

Patients currently receiving other anticancer agents.

Patients currently receiving other investigational agents.

Sexes Eligible for Study: All
up to 30 Years   (Child, Adult)
No
Contact: Stephanie Forlenza, MA 202-476-6841 saforlenza@childrensnational.org
United States
 
 
NCT02076906
HIFU3917
No
Not Provided
Not Provided
AeRang Kim, Children's Research Institute
AeRang Kim
Not Provided
Principal Investigator: AeRang Kim, MD, PhD Children's Research Institute
Children's Research Institute
June 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP